Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

34.45 -1.31 (-3.68%)

Streaming Delayed Price Updated: 11:08 AM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	289,883
Open	35.56
Bid (Size)	34.33 (100)
Ask (Size)	34.56 (100)
Prev. Close	35.76
Today's Range	33.71 - 35.77
52wk Range	14.06 - 42.00
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

February 18, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Performance

YTD	-2.1%	-2.1%
1 Month	+6.3%	+6.3%
3 Month	-10.8%	-10.8%
6 Month	+41.6%	+41.6%
1 Year	+71.9%	+71.9%

More News

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

February 04, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

January 09, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2026

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

November 25, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Via The Motley Fool

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Via The Motley Fool

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Via The Motley Fool

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Via The Motley Fool

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Via The Motley Fool

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

November 05, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

October 30, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗

October 20, 2025

Via Benzinga

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

September 24, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts ↗

August 25, 2025

Via Benzinga

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

August 25, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

August 18, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co ↗

August 07, 2025

Via Benzinga

NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗

August 06, 2025

Via The Motley Fool

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

August 06, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

July 30, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025

July 22, 2025

From NewAmsterdam Pharma N.V.

Via GlobeNewswire

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?

Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.

What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?

NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?

The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market

What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?

The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 34.45

When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?

The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 02/19/26 11:08 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.